🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Gregor Krings

Cleveland Clinic

ORCID: 0000-0002-5285-0862
Biochemistry, Genetics and Molecular BiologyMedicineChemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity”.

Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity

Modern Pathology(2020)10.1038/s41379-019-0442-2
N/A
0DataRank · unranked
60 citations

Edaise M. da Silva, Denise Frosina, Felipe C. Geyer, John R. Lozada, Thais Basili +21 more

Evaluation of ductal carcinoma in situ grade via triple-modal molecular imaging of B7-H3 expression

npj Breast Cancer(2020)10.1038/s41523-020-0158-y
N/A
0DataRank · unranked
19 citations

Gregory R. Bean, Gregor Krings, Katheryne E. Wilson, Sunitha V. Bachawal

A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1076
N/A
0DataRank · unranked
19 citations

Amelia S. Gliwa, Siti Rahmaputri, H Dittrich, Melanie Majure, Hope S. Rugo +10 more

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

The Lancet Oncology(2021)10.1016/s1470-2045(21)00589-1
N/A
0DataRank · unranked
447 citations

Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze +94 more

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Annals of Oncology(2021)10.1016/j.annonc.2021.02.011
N/A
0DataRank · unranked
45 citations

Christina Yau, Lamorna Brown Swigart, Rebekah Gould, Gregor Krings, Gillian L. Hirst +27 more

Inflammation Mediates the Development of Aggressive Breast Cancer Following Radiotherapy

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3215
N/A
0DataRank · unranked
25 citations

Alba Gonzàlez-Juncà, Yufei Zheng, Haoxu Ouyang, Irineu Illa-Bochaca, Kathleen C. Horst +6 more

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Annals of Oncology(2022)10.1016/j.annonc.2022.04.072
N/A
0DataRank · unranked
21 citations

Anna Mrukwa, Christina Yau, Denise M. Wolf, Y.-Y. Chen, Ronald Balassanian +26 more

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2256
N/A
0DataRank · unranked
20 citations

Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien +44 more

A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3104
N/A
0DataRank · unranked
3 citations

W. Kimryn Rathmell, Geoffrey I. Shapiro, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A. Trikalinos +9 more